Rice Bodies in Tuberculous Tenosynovitis of Wrist.

Latika Gupta,Vikas Gupta,T. Kumar

DOI: https://doi.org/10.1016/j.reuma.2017.08.003

2017-11-02

Reumatología Clínica

Abstract:

What problem does this paper attempt to address?

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Hong Lian,Alexandra Litvinchuk,Angie C-A Chiang,Nadia Aithmitti,Joanna L Jankowsky,Hui Zheng

DOI: https://doi.org/10.1523/JNEUROSCI.2117-15.2016

2016-01-01

Journal of Neuroscience

Abstract:Increasing evidence supports a role of neuroinflammation in the pathogenesis of Alzheimer's disease (AD). Previously, we identified a neuron glia signaling pathway whereby A beta acts as an upstream activator of astroglial nuclear factor kappa B (NE-kappa B), leading to the release of complement C3, which acts on the neuronal C3a receptor (C3aR) to influence dendritic morphology and cognitive function. Here we report that astrocytic complement activation also regulates A beta dynamics in vitro and amylo id pathology in AD mouse models through microglial C3aR. We show that in primary microglial cultures, acute C3 or C3a activation promotes, whereas chronic C3/C3a treatment attenuates, microglial phagocytosis and that the effect of chronic C3 exposure can be blocked by cotreatment with a C3aR antagonist and by genetic deletion of C3aR. We further demonstrate that A beta pathology and neuroinflammation in amyloid precursor protein (APP) transgenic mice are worsened by astroglial NE-kappa B hyperactivat ion and resulting C3 elevation, whereas treatment with the C3aR antagonist (C3aRA) ameliorates plaque load and microgliosis. Our studies define a complement-dependent intercellular cross talk in which neuronal overproduction of A beta activates astroglial NE-kappa B to elicit extracellular release of C3. This promotes a pathogenic cycle by which C3 in turn interacts with neuronal and microglial C3aR to alter cognitive function and impair A beta phagocytosis. This feedforward loop can be effectively blocked by C3aR inhibition, supporting the therapeutic potential of C3aR antagonists under chronic neuro inflammation conditions.
Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer's model

Amira Sayed Hanafy,Alf Lamprecht,Dirk Dietrich

DOI: https://doi.org/10.1186/s12987-023-00492-7

2023-11-22

Abstract:Background: Parenchymal accumulation of beta-amyloid (Aβ) characterizes Alzheimer's disease (AD). Aβ homeostasis is maintained by two ATP-binding cassette (ABC) transporters (ABCC1 and ABCB1) mediating efflux, and the receptor for advanced glycation end products (RAGE) mediating influx across the blood-brain barrier (BBB). Altered transporter levels and disruption of tight junctions (TJ) were linked to AD. However, Aβ transport and the activity of ABCC1, ABCB1 and RAGE as well as the functionality of TJ in AD are unclear. Methods: ISMICAP, a BBB model involving microperfusion of capillaries, was used to assess BBB properties in acute cortical brain slices from Tg2576 mice compared to wild-type (WT) controls using two-photon microscopy. TJ integrity was tested by vascularly perfusing biocytin-tetramethylrhodamine (TMR) and quantifying its extravascular diffusion as well as the diffusion of FM1-43 from luminal to abluminal membranes of endothelial cells (ECs). To assess ABCC1 and ABCB1 activity, calcein-AM was perfused, which is converted to fluorescent calcein in ECs and gets actively extruded by both transporters. To probe which transporter is involved, probenecid or Elacridar were applied, individually or combined, to block ABCC1 and ABCB1, respectively. To assess RAGE activity, the binding of 5-FAM-tagged Aβ by ECs was quantified with or without applying FPS-ZM1, a RAGE antagonist. Results: In Tg2576 mouse brain, extravascular TMR was 1.8-fold that in WT mice, indicating increased paracellular leakage. FM1-43 staining of abluminal membranes in Tg2576 capillaries was 1.7-fold that in WT mice, indicating reduced TJ integrity in AD. While calcein was undetectable in WT mice, its accumulation was significant in Tg2576 mice, suggesting lower calcein extrusion in AD. Incubation with probenecid or Elacridar in WT mice resulted in a marked calcein accumulation, yet probenecid alone had no effect in Tg2576 mice, implying the absence of probenecid-sensitive ABC transporters. In WT mice, Aβ accumulated along the luminal membranes, which was undetectable after applying FPS-ZM1. In contrast, marginal Aβ fluorescence was observed in Tg2576 vessels, and FPS-ZM1 was without effect, suggesting reduced RAGE binding activity. Conclusions: Disrupted TJ integrity, reduced ABCC1 functionality and decreased RAGE binding were identified as BBB alterations in Tg2576 mice, with the latter finding challenging the current concepts. Our results suggest to manage AD by including modulation of TJ proteins and Aβ-RAGE binding.
A differentiating neural stem cell-derived astrocytic population mitigates the inflammatory effects of TNF-α and IL-6 in an iPSC-based blood-brain barrier model

Jennifer L. Mantle,Kelvin H. Lee

DOI: https://doi.org/10.1016/j.nbd.2018.07.030

IF: 7.046

2018-11-01

Neurobiology of Disease

Abstract:Inflammation can be a risk factor for neurodegenerative diseases such as Alzheimer's disease (AD) and may also contribute to the progression of AD. Here, we sought to understand how inflammation affects the properties of the brain microvascular endothelial cells (BMECs) that compose the blood-brain barrier (BBB), which is impaired in AD. A fully human in vitro BBB model with brain microvascular endothelial cells derived from induced pluripotent stem cells and differentiating neural stem cell (NSC)-derived astrocytic cells was used to investigate the effects of neuroinflammation on barrier function. The cytokines TNF-α and IL-6 directly cause BBB dysfunction measured by a decrease in transendothelial electrical resistance, an increase in sodium fluorescein permeability, and a decrease in cell polarity, providing a link between neuroinflammation and specific aspects of BBB breakdown. An NSC-derived astrocytic cell population was added to the model and secreted cytokines and chemokines were quantified in monoculture and coculture both in the presence and absence of TNF-α and IL-6. Increased concentrations of pro-inflammatory cytokines known to be secreted by astrocytes or endothelial cells such as MCP-1, IL-8, IP-10, MIP-1β, IL-1 β, MIG, and RANTES peaked in inflammatory conditions when NSC-astrocytic cells were present. Despite the presence of several pro-inflammatory cytokines, the NSC-derived astrocytic cells mitigated the effects of inflammation measured by a restoration of transendothelial electrical resistance and IgG permeability. These results also suggest a breakdown in transcellular transport that precedes any increase in paracellular permeability in neuroinflammation. This model has the potential to resolve questions about neurodegenerative disease progression and delivery of therapeutics to the brain.

neurosciences
A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1–42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model

Nimish K. Acharya,Henya C. Grossman,Peter M. Clifford,Eli C. Levin,Kenneth R. Light,Hana Choi,Randel L. Swanson II,Mary C. Kosciuk,Venkat Venkataraman,David J. Libon,Louis D. Matzel,Robert G. Nagele

DOI: https://doi.org/10.3233/jad-231028

2024-02-21

Journal of Alzheimer s Disease

Abstract:Background: Increased blood-brain barrier (BBB) permeability and amyloid-β (Aβ) peptides (especially Aβ1–42) (Aβ42) have been linked to Alzheimer's disease (AD) pathogenesis, but the nature of their involvement in AD-related neuropathological changes leading to cognitive changes remains poorly understood. Objective: To test the hypothesis that chronic extravasation of bloodborne Aβ42 peptide and brain-reactive autoantibodies and their entry into the brain parenchyma via a permeable BBB contribute to AD-related pathological changes and cognitive changes in a mouse model. Methods: The BBB was rendered chronically permeable through repeated injections of Pertussis toxin (PT), and soluble monomeric, fluorescein isothiocyanate (FITC)-labeled or unlabeled Aβ42 was injected into the tail-vein of 10-month-old male CD1 mice at designated intervals spanning ∼3 months. Acquisition of learned behaviors and long-term retention were assessed via a battery of cognitive and behavioral tests and linked to neuropathological changes. Results: Mice injected with both PT and Aβ42 demonstrated a preferential deficit in the capacity for long-term retention and an increased susceptibility to interference in selective attention compared to mice exposed to PT or saline only. Immunohistochemical analyses revealed increased BBB permeability and entry of bloodborne Aβ42 and immunoglobulin G (IgG) into the brain parenchyma, selective neuronal binding of IgG and neuronal accumulation of Aβ42 in animals injected with both PT and Aβ42 compared to controls. Conclusion: Results highlight the potential synergistic role of BBB compromise and the influx of bloodborne Aβ42 into the brain in both the initiation and progression of neuropathologic and cognitive changes associated with AD.

neurosciences
Role of Blood-Brain Barrier in Alzheimer's Disease

Zhiyou Cai,Pei-Feng Qiao,Cheng-Qun Wan,Min Cai,Nan-Kai Zhou,Qin Li

DOI: https://doi.org/10.3233/JAD-180098

Abstract:The blood-brain barrier (BBB) is involved in the pathogenesis of Alzheimer's disease (AD). BBB is a highly selective semipermeable structural and chemical barrier which ensures a stable internal environment of the brain and prevents foreign objects invading the brain tissue. BBB dysfunction induces the failure of Aβ transport from brain to the peripheral circulation across the BBB. Especially, decreased levels of LRP-1 (low density lipoprotein receptor-related protein 1) and increased levels of RAGE (receptor for advanced glycation endproducts) at the BBB can cause the failure of Aβ transport. The pathogenesis of AD is related to the BBB structural components, including pericytes, astrocytes, vascular endothelial cells, and tight junctions. BBB dysfunction will trigger neuroinflammation and oxidative stress, then enhance the activity of β-secretase and γ-secretase, and finally promote Aβ generation. A progressive accumulation of Aβ in brain and BBB dysfunction may become a feedback loop that gives rise to cognitive impairment and the onset of dementia. The correlation between BBB dysfunction and tau pathology has been well-reported. Therefore, regulating BBB function may be a new therapeutic target for treating AD.
Aβ1–42 oligomer‐induced leakage in an in vitro blood–brain barrier model is associated with up‐regulation of RAGE and metalloproteinases, and down‐regulation of tight junction scaffold proteins

Chunyan Zhang,B. Kalionis,Xiantao Tai,Yaming Li,Lan Cao,W. Wan,S. Xia,Lumei Liu

DOI: https://doi.org/10.1111/jnc.13122

2015-07-01

Journal of Neurochemistry

Abstract:Accumulating evidence indicates that abnormal deposition of amyloid‐β (Aβ) peptide in the brain is responsible for endothelial cell damage and consequently leads to blood–brain barrier (BBB) leakage. However, the mechanisms underlying BBB disruption are not well described. We employed an monolayer BBB model comprising bEnd.3 cell and found that BBB leakage was induced by treatment with Aβ1–42, and the levels of tight junction (TJ) scaffold proteins (ZO‐1, Claudin‐5, and Occludin) were decreased. Through comparisons of the effects of the different components of Aβ1–42, including monomer (Aβ1–42‐Mono), oligomer (Aβ1–42‐Oligo), and fibril (Aβ1–42‐Fibril), our data confirmed that Aβ1–42‐Oligo is likely to be the most important damage factor that results in TJ damage and BBB leakage in Alzheimer's disease. We found that the incubation of bEnd.3 cells with Aβ1–42 significantly up‐regulated the level of receptor for advanced glycation end‐products (RAGE). Co‐incubation of a polyclonal antibody to RAGE and Aβ1–42‐Oligo in bEnd.3 cells blocked RAGE suppression of Aβ1–42‐Oligo‐induced alterations in TJ scaffold proteins and reversed Aβ1–42‐Oligo‐induced up‐regulation of RAGE, matrix metalloproteinase (MMP)‐2, and MMP‐9. Furthermore, we found that these effects induced by Aβ1–42‐Oligo treatment were effectively suppressed by knockdown of RAGE using small interfering RNA (siRNA) transfection. We also found that GM 6001, a broad‐spectrum MMP inhibitor, partially reversed the Aβ1–42‐Oligo‐induced inhibitor effects in bEnd.3 cells. Thus, these results suggested that RAGE played an important role in Aβ‐induced BBB leakage and alterations of TJ scaffold proteins, through a mechanism that involved up‐regulation of MMP‐2 and MMP‐9. To reveal the role of RAGE in blood–brain barrier (BBB) disruption in Alzheimer's disease (AD), we employed an monolayer BBB model comprising bEnd.3 cell and found that BBB leakage was induced by treatment with amyloid‐β (Aβ), and the levels of tight junction (TJ) scaffold proteins including ZO‐1, Claudin‐5, and Occludin were decreased. Using receptor for advanced glycation end‐products (RAGE) neutralizing polyclonal antibody and siRNA, we confirmed that RAGE played an important role in Aβ‐induced BBB leakage and alterations of TJ scaffold proteins and in the up‐regulation of matrix metalloproteinase‐2 (MMP‐2) and matrix metalloproteinase‐9 (MMP‐9). NF‐κB, nuclear factor kappa‐light‐chain‐enhancer of activated B cells.

Chemistry,Biology,Medicine
Inhibition of β-catenin signaling by Amyloid-β in endothelial cells impairs vascular barrier integrity

Joseph W Leasure,Thi Mai,Avi Fogel,Pierina Danos,Li Wang,Mark A Sanborn,Zijing Ye,Young-Mee Kim,Xinhe Wang,Jennifer Flores,Muzamil Mushtaq,Peter T Toth,Sang-Ging Ong,Orly Lazarov,Jalees Rehman

DOI: https://doi.org/10.1101/2024.11.05.622172

2024-11-05

Abstract:Dysfunction of the blood-brain barrier (BBB) is emerging as a critical mediator of Alzheimer's Disease (AD) progression and precedes the formation of large Amyloid-β (Aβ) plaques in AD patients. Maintenance of the blood brain barrier integrity by brain microvascular endothelial cells (BMECs) is essential for brain homeostasis and is in part maintained by WNT/β-catenin signaling. We hypothesized that Aβ induces blood-brain barrier dysfunction by inhibiting WNT/β-catenin signaling in brain endothelial cells, leading to reduced expression of BBB-related genes and barrier function. In brain endothelial cells, we found that Aβ directly decreased β-catenin transcriptional activity, but also inhibited activation of β-catenin by the WNT3A peptide. Additionally, Aβ reduced barrier integrity of ECs, which was in part restored by exposure to exogenous WNT3A. We observed Aβ-induced inhibition within 3 hours of exposure. Aβ-induced inhibition of β-catenin signaling was consistent across both immortalized brain ECs and ECs differentiated from human induced pluripotent stem cells(iPSCs). We next investigated human iPSCs with and without the N141I mutation in presenilin-2 (PSEN2), known to increase Aβ buildup and familial AD risk. We found the AD ECs showed smaller cell size and expressed lower VE-cadherin at the protein level. RNA sequencing revealed that the presence of PSEN2 N141I did not significantly impact gene expression of genes coding for proteins canonically involved in barrier integrity but did show differences in the expression of transposable elements. These results indicate that BBB dysfunction early in AD may be the result of Aβ in the brain impairing WNT/β-catenin signaling which maintains the barrier integrity of brain endothelial cells.

Neuroscience
Towards joint disease mapping

L. Held,Isabel Natário,S. Fenton,H. Rue,N. Becker

DOI: https://doi.org/10.1191/0962280205sm389oa

IF: 2.494

2005-02-01

Statistical Methods in Medical Research

Abstract:This article discusses and extends statistical models to jointly analyse the spatial variation of rates of several diseases with common risk factors. We start with a review of methods for separate analyses of diseases, then move to ecological regression approaches, where the rates from one of the diseases enter as surrogate covariates for exposure. Finally, we propose a general framework for jointly modelling the variation of two or more diseases, some of which share latent spatial fields, but with possibly different risk gradients. In our application, we consider mortality data on oral, oesophagus, larynx and lung cancers for males in Germany, which all share smoking as a common risk factor. Furthermore, the first three cancers are also known to be related to excessive alcohol consumption. An empirical comparison of the different models based on a formal model criterion as well as on the posterior precision of the relative risk estimates strongly suggests that the joint modelling approach is a useful and valuable extension over individual analyses.
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease

Yan-Li Zhang,Juan Wang,Zhi-Na Zhang,Qiang Su,Jun-Hong Guo

DOI: https://doi.org/10.4103/1673-5374.335829

2022-01-01

Neural Regeneration Research

Abstract:Neurovascular dysfunction, as an integral part of Alzheimer's disease, may have an important influence on the onset and progression of chronic neurodegenerative processes. The blood-brain barrier (BBB) pathway is one of the main pathways that mediates the clearance of amyloid-beta (Aβ) in the brain parenchyma. A large number of studies have shown that receptors and ATP-binding cassette transporters expressed on endothelial cells play an important role in Aβ transport across the BBB, but the specific mechanism is not clear. In this review, we summarize the possible mechanisms of Aβ production and clearance, and in particular the relationship between Aβ and brain capillary endothelial cells. Aβ is produced by abnormal cleavage of the amyloid precursor protein via amyloidogenic processing under pathological conditions. Dysregulation of Aβ clearance is considered to be the main reason for the massive accumulation of Aβ in the brain parenchyma. Several pathways mediating Aβ clearance from the brain into the periphery have been identified, including the BBB pathway, the blood-cerebrospinal fluid barrier and arachnoid granule pathway, and the lymphoid-related pathway. Brain capillary endothelial cells are the key components of Aβ clearance mediated by BBB. Receptors (such as LRP1, RAGE, and FcRn) and ATP-binding cassette transporters (such as P-gp, ABCA1, and ABCC1) expressed on endothelial cells play a critical role in Aβ transcytosis across the BBB. The toxic effects of Aβ can induce dysregulation of receptor and transporter expression on endothelial cells. Excessive Aβ exerts potent detrimental cerebrovascular effects by promoting oxidative stress, inducing chronic inflammation, and impairing endothelial structure and functions. All of these are main causes for the reduction in Aβ clearance across the BBB and the accumulation of Aβ in the brain parenchyma. Therefore, studies on the interactions between Aβ and brain capillary endothelial cells, including their receptors and transporters, studies on inhibition of the toxic effects of Aβ on endothelial cells, and studies on promoting the ability of endothelial cells to mediate Aβ clearance may provide new therapeutic strategies for Aβ clearance in Alzheimer's disease.

neurosciences,cell biology
ZNF787 and HDAC1 Mediate Blood–Brain Barrier Permeability in an In Vitro Model of Alzheimer's Disease Microenvironment

Lu Zhang,Baicheng Zhu,Xinxin Zhou,Hao Ning,Fengying Zhang,Bingju Yan,Jiajia Chen,Teng Ma

DOI: https://doi.org/10.1007/s12640-024-00693-4

IF: 3.9781

2024-02-09

Neurotoxicity Research

Abstract:The permeability of the blood–brain barrier (BBB) is increased in Alzheimer's disease (AD). This plays a key role in the instigation and maintenance of chronic inflammation during AD. Experiments using AD models showed that the increased permeability of the BBB was mainly caused by the decreased expression of tight junction-related proteins occludin and claudin-5. In this study, we found that ZNF787 and HDAC1 were upregulated in β-amyloid (Aβ) 1–42 -incubated endothelial cells, resulting in increased BBB permeability. Conversely, the silencing of ZNF787 and HDAC1 by RNAi led to reduced BBB permeability. The silencing of ZNF787 and HDAC1 enhanced the expression of occludin and claudin-5. Mechanistically, ZNF787 binds to promoter regions for occludin and claudin-5 and functions as a transcriptional regulator. Furthermore, we demonstrate that ZNF787 interacts with HDAC1, and this resulted in the downregulation of the expression of genes encoding tight junction-related proteins to increase in BBB permeability. Taken together, our study identifies critical roles for the interaction between ZNF787 and HDAC1 in regulating BBB permeability and the pathogenesis of AD.

neurosciences
Sonographic demonstration of gas in torsed gangrenous adnexa

Neil B. Cooper,P. Athey

DOI: https://doi.org/10.1002/jcu.1870130307

1985-03-01

Journal of Clinical Ultrasound

Abstract:Torsion of the uterine adnexa is a well-recognized gynecological Rapid diagnosis
New insight into neurological degeneration: Inflammatory cytokines and blood–brain barrier

Jie Yang,Mingzi Ran,Hongyu Li,Ye Lin,Kui Ma,Yuguang Yang,Xiaobing Fu,Siming Yang

DOI: https://doi.org/10.3389/fnmol.2022.1013933

2022-10-24

Frontiers in Molecular Neuroscience

Abstract:Neurological degeneration after neuroinflammation, such as that resulting from Alzheimer's disease (AD), stroke, multiple sclerosis (MS), and post-traumatic brain injury (TBI), is typically associated with high mortality and morbidity and with permanent cognitive dysfunction, which places a heavy economic burden on families and society. Diagnosing and curing these diseases in their early stages remains a challenge for clinical investigation and treatment. Recent insight into the onset and progression of these diseases highlights the permeability of the blood–brain barrier (BBB). The primary factor that influences BBB structure and function is inflammation, especially the main cytokines including IL-1β, TNFα, and IL-6, the mechanism on the disruption of which are critical component of the aforementioned diseases. Surprisingly, the main cytokines from systematic inflammation can also induce as much worse as from neurological diseases or injuries do. In this review, we will therefore discuss the physiological structure of BBB, the main cytokines including IL-1β, TNFα, IL-6, and their mechanism on the disruption of BBB and recent research about the main cytokines from systematic inflammation inducing the disruption of BBB and cognitive impairment, and we will eventually discuss the need to prevent the disruption of BBB.

neurosciences
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease

Robert D Bell,Berislav V Zlokovic

DOI: https://doi.org/10.1007/s00401-009-0522-3

Abstract:Vascular dysfunction has a critical role in Alzheimer's disease (AD). Recent data from brain imaging studies in humans and animal models suggest that cerebrovascular dysfunction may precede cognitive decline and onset of neurodegenerative changes in AD and AD models. Cerebral hypoperfusion and impaired amyloid beta-peptide (Abeta) clearance across the blood-brain barrier (BBB) may contribute to the onset and progression of dementia AD type. Decreased cerebral blood flow (CBF) negatively affects the synthesis of proteins required for memory and learning, and may eventually lead to neuritic injury and neuronal death. Impaired clearance of Abeta from the brain by the cells of the neurovascular unit may lead to its accumulation on blood vessels and in brain parenchyma. The accumulation of Abeta on the cerebral blood vessels, known as cerebral amyloid angiopathy (CAA), is associated with cognitive decline and is one of the hallmarks of AD pathology. CAA can severely disrupt the integrity of the blood vessel wall resulting in micro or macro intracerebral bleedings that exacerbates neurodegenerative process and inflammatory response and may lead to hemorrhagic stroke, respectively. Here, we review the role of the neurovascular unit and molecular mechanisms in vascular cells behind AD and CAA pathogenesis. First, we discuss apparent vascular changes, including the cerebral hypoperfusion and vascular degeneration that contribute to different stages of the disease process in AD individuals. We next discuss the role of the low-density lipoprotein receptor related protein-1 (LRP), a key Abeta clearance receptor at the BBB and along the cerebrovascular system, whose expression is suppressed early in AD. We also discuss how brain-derived apolipoprotein E isoforms may influence Abeta clearance across the BBB. We then review the role of two interacting transcription factors, myocardin and serum response factor, in cerebral vascular cells in controlling CBF responses and LRP-mediated Abeta clearance. Finally, we discuss the role of microglia and perivascular macrophages in Abeta clearance from the brain. The data reviewed here support an essential role of neurovascular and BBB mechanisms in contributing to both, onset and progression of AD.
Complication of benign tracheobronchial strictures by self-expanding metal stents.

H. Gaissert,H. Grillo,C. Wright,D. Donahue,J. Wain,D. Mathisen

DOI: https://doi.org/10.1016/S0022-5223(03)00361-1

IF: 6.439

2003-09-01

Journal of Thoracic and Cardiovascular Surgery

Abstract:
The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders

Ying-Chieh Wu,Tizibt Ashine Bogale,Jari Koistinaho,Marina Pizzi,Taisia Rolova,Arianna Bellucci

DOI: https://doi.org/10.1007/s00401-024-02696-z

IF: 15.887

2024-02-14

Acta Neuropathologica

Abstract:Central nervous system (CNS) accumulation of fibrillary deposits made of Amyloid β (A β ), hyperphosphorylated Tau or α -synuclein ( α -syn), present either alone or in the form of mixed pathology, characterizes the most common neurodegenerative diseases (NDDs) as well as the aging brain. Compelling evidence supports that acute neurological disorders, such as traumatic brain injury (TBI) and stroke, are also accompanied by increased deposition of toxic A β , Tau and α -syn species. While the contribution of these pathological proteins to neurodegeneration has been experimentally ascertained, the cellular and molecular mechanisms driving A β , Tau and α -syn-related brain damage remain to be fully clarified. In the last few years, studies have shown that A β , Tau and α -syn may contribute to neurodegeneration also by inducing and/or promoting blood–brain barrier (BBB) disruption. These pathological proteins can affect BBB integrity either directly by affecting key BBB components such as pericytes and endothelial cells (ECs) or indirectly, by promoting brain macrophages activation and dysfunction. Here, we summarize and critically discuss key findings showing how A β , Tau and α -syn can contribute to BBB damage in most common NDDs, TBI and stroke. We also highlight the need for a deeper characterization of the role of these pathological proteins in the activation and dysfunction of brain macrophages, pericytes and ECs to improve diagnosis and treatment of acute and chronic neurological disorders.

pathology,neurosciences,clinical neurology
Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation

Ayman ElAli,Peter Thériault,Paul Préfontaine,Serge Rivest

DOI: https://doi.org/10.1186/2051-5960-1-75

2013-11-13

Abstract:Background: The Blood-brain barrier (BBB) controls brain supply with oxygen and nutrients, and protects the brain from toxic metabolites, such as beta-amyloid (Aβ) peptides. The neurovascular unit (NVU) couples vascular and neuronal functions by controlling BBB parameters based on brain needs. As such, NVU/BBB dysfunction, associated to irregularities in cerebral blood flow (CBF), has been proposed to contribute in the pathogenesis of Alzheimer's disease (AD), mainly by impairing cerebral Aβ clearance. However, the spatiotemporal contribution of the NVU/BBB in the neurodegenerative cascades remains elusive. Results: By using C57BL/6J mice subjected to right common carotid artery (rCCA) permanent ligation in order to induce mild chronic cerebral hypoperfusion, we show here that cerebral hypoperfusion induced NVU dysfunction by reducing ABCB1 protein expression in brain capillaries. ABCB1 reduction was mainly triggered by an enhanced Glycogen Synthase Kinase 3 (GSK3β) activation, which decreased β-catenin nuclear abundance. Moreover, cerebral hypoperfusion triggered early vascular deposition of peripherally applied human Aβ1-42 peptides, which has shifted from highly vascular to the parenchyma 6 weeks later, forming small stable Aβ deposits. Hypoperfusion induced a deregulation in glucose metabolism, as brain reperfusion, or the administration of a high dose of glucose, diminished GSK3β activation, recuperated β-catenin nuclear abundance, reestablished ABCB1 protein expression, and prevented Aβ vascular early deposition. These results demonstrate that mild chronic cerebral hypoperfusion creates a metabolically deregulated microenvironment, thus triggering the brain entry and aggregation of peripherally applied human Aβ1-42 peptides. Conclusion: Our study offers new insights on the initiation of the neurodegenerative cascades observed in AD, which could be valuable in developing adequate treatment strategies.
Managed Care and Mental Health Services: Lessons for Health Care Providers

J. Schuster

DOI: https://doi.org/10.1177/0885713X9300800408

1993-12-01

American Journal of Medical Quality

Abstract:Managed health care has grown rapidly during the past decade and is likely to continue its expansion during the next several years. Psychiatric services have been subject to especially stringent efforts to control costs, including intensive utilization review and formation of provider networks that primarily utilize master level professionals. Psychiatrists' re sponses to these changes have ranged from antago nistic to proactive. The most effective actions are proactive ones that attempt to shape these new health care systems. A thorough understanding of the impact of managed care upon psychiatry and of psychiatrists' responses can help providers in other medical spe cialties as they develop their own strategies to cope with the changing health care environment.
The Potential Mechanisms of Aβ-receptor for Advanced Glycation End-Products Interaction Disrupting Tight Junctions of the Blood-Brain Barrier in Alzheimer's Disease.

Wenbin Wan,Huixian Chen,Yaming Li

DOI: https://doi.org/10.3109/00207454.2013.825258

2013-01-01

International Journal of Neuroscience

Abstract:The receptor for advanced glycation end-products (RAGE) is a multiligand membrane receptor that has been implicated in the cytotoxicity effects of β-amyloid protein (Aβ) in AD. Positive feedback mechanism of RAGE within blood-brain barrier (BBB) and/or cells inside the brain is proposed, including interaction with Aβ stimulating activation of proinflammatory cytokines, release of reactive oxygen species (ROS), which leads to neuron damage and BBB dysfunction. RAGE is the main factor mediating Aβ cytotoxicity. Attenuation of RAGE activity may inhibit Aβ from accumulation in the cerebral blood vessels and prevent neurotoxicity. Furthermore, RAGE may serve as a therapeutic target for Alzheimer's disease by inhibiting pathophysiological consequences of Aβ-RAGE interaction. Tight junctions (TJ) are identified as the basic structure of the BBB and RAGE-mediated Aβ cytotoxicity to the brain microvascular endothelial cells (BMEC), resulting in damaged BBB structural integrity. However, the potential mechanism is poorly studied.
Post-translational modifications of beta-amyloid alter its transport in the blood-brain barrier in vitro model

Kseniya B. Varshavskaya,Irina Yu Petrushanko,Vladimir A. Mitkevich,Evgeny P. Barykin,Alexander A. Makarov

DOI: https://doi.org/10.3389/fnmol.2024.1362581

2024-03-08

Frontiers in Molecular Neuroscience

Abstract:One of the hallmarks of Alzheimer's disease (AD) is the accumulation of beta-amyloid peptide (Aβ) leading to formation of soluble neurotoxic Aβ oligomers and insoluble amyloid plaques in various parts of the brain. Aβ undergoes post-translational modifications that alter its pathogenic properties. Aβ is produced not only in brain, but also in the peripheral tissues. Such Aβ, including its post-translationally modified forms, can enter the brain from circulation by binding to RAGE and contribute to the pathology of AD. However, the transport of modified forms of Aβ across the blood–brain barrier (BBB) has not been investigated. Here, we used a transwell BBB model as a controlled environment for permeability studies. We found that Aβ 42 containing isomerized Asp7 residue (iso-Aβ 42 ) and Aβ 42 containing phosphorylated Ser8 residue (pS8-Aβ 42 ) crossed the BBB better than unmodified Aβ 42 , which correlated with different contribution of endocytosis mechanisms to the transport of these isoforms. Using microscale thermophoresis, we observed that RAGE binds to iso-Aβ 42 an order of magnitude weaker than to Aβ 42 . Thus, post-translational modifications of Aβ increase the rate of its transport across the BBB and modify the mechanisms of the transport, which may be important for AD pathology and treatment.

neurosciences
Endothelial Dysfunctions in Blood–Brain Barrier Breakdown in Alzheimer's Disease: From Mechanisms to Potential Therapies

Qian Yue,Xinyue Leng,Ningqing Xie,Zaijun Zhang,Deguang Yang,Maggie Pui Man Hoi

DOI: https://doi.org/10.1111/cns.70079

2024-11-23

CNS Neuroscience & Therapeutics

Abstract:Blood–brain barrier (BBB) works as a crucial structure separating central nervous system (CNS) and circulating system. The highly organized endothelial junctions and transporters strictly restricts substance exchange across BBB to maintain the homeostasis of CNS. In Alzheimer's disease, BBB breakdown has been widely detected, featured as a series of brain endothelial cell (BEC) pathologies, including increased permeability, abnormal levels and functions of influx and efflux transporters, as well as inflammatory and oxidative profile. The goal for BEC‐targeting treatment in AD is to maintain the integrity of BBB and accelerate the clearance of brain‐derived Aβ species through BBB. BEC‐targeting treatment for AD mainly focuses on regulating a series of pathological processes including inflammation, oxidative stress, autophagy, apoptosis, and several signaling such as angiogenic and Wnt/β‐catenin pathway, as well as modulating Aβ clearance pathway and so on. Targeting various BEC pathologies have shown therapeutic potentials in protecting BBB and improving cognitive functions in AD. Recent research has shown the presence of blood–brain barrier (BBB) breakdown in Alzheimer's disease (AD). BBB is a dynamic interface consisting of a continuous monolayer of brain endothelial cells (BECs) enveloped by pericytes and astrocytes. The restricted permeability of BBB strictly controls the exchange of substances between blood and brain parenchyma, which is crucial for brain homeostasis by excluding blood‐derived detrimental factors and pumping out brain‐derived toxic molecules. BBB breakdown in AD is featured as a series of BEC pathologies such as increased paracellular permeability, abnormal levels and functions of transporters, and inflammatory or oxidative profile, which may disturb the substance transportation across BBB, thereafter induce CNS disorders such as hypometabolism, Aβ accumulation, and neuroinflammation, eventually aggravate cognitive decline. Therefore, it seems important to protect BEC properties for BBB maintenance and neuroprotection. In this review, we thoroughly summarized the pathological alterations of BEC properties reported in AD patients and numerous AD models, including paracellular permeability, influx and efflux transporters, and inflammatory and oxidative profiles, and probably associated underlying mechanisms. Then we reviewed current therapeutic agents that are effective in ameliorating a series of BEC pathologies, and ultimately protecting BBB integrity and cognitive functions. Regarding the current drug development for AD proceeds extremely hard, this review aims to discuss the therapeutic potentials of targeting BEC pathologies and BBB maintenance for AD treatment, therefore expecting to shed a light on the future AD drug development by targeting BEC pathologies and BBB protection.

pharmacology & pharmacy,neurosciences

Rice Bodies in Tuberculous Tenosynovitis of Wrist.

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer's model

A differentiating neural stem cell-derived astrocytic population mitigates the inflammatory effects of TNF-α and IL-6 in an iPSC-based blood-brain barrier model

A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1–42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model

Role of Blood-Brain Barrier in Alzheimer's Disease

Aβ1–42 oligomer‐induced leakage in an in vitro blood–brain barrier model is associated with up‐regulation of RAGE and metalloproteinases, and down‐regulation of tight junction scaffold proteins

Inhibition of β-catenin signaling by Amyloid-β in endothelial cells impairs vascular barrier integrity

Towards joint disease mapping

The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease

ZNF787 and HDAC1 Mediate Blood–Brain Barrier Permeability in an In Vitro Model of Alzheimer's Disease Microenvironment

Sonographic demonstration of gas in torsed gangrenous adnexa

New insight into neurological degeneration: Inflammatory cytokines and blood–brain barrier

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease

Complication of benign tracheobronchial strictures by self-expanding metal stents.

The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders

Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation

Managed Care and Mental Health Services: Lessons for Health Care Providers

The Potential Mechanisms of Aβ-receptor for Advanced Glycation End-Products Interaction Disrupting Tight Junctions of the Blood-Brain Barrier in Alzheimer's Disease.

Post-translational modifications of beta-amyloid alter its transport in the blood-brain barrier in vitro model

Endothelial Dysfunctions in Blood–Brain Barrier Breakdown in Alzheimer's Disease: From Mechanisms to Potential Therapies